BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38132703)

  • 21. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
    Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
    Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
    Sarper N; Gelen SA; Zengin E; Demirsoy U; Erçin C
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):486-7. PubMed ID: 26181421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
    Unal S; Cetin M; Kutlay NY; Elmas SA; Gumruk F; Tukun A; Tuncer M; Gurgey A
    Ann Hematol; 2010 Apr; 89(4):359-64. PubMed ID: 19798502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
    Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
    Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
    Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
    Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
    Cavé H; Caye A; Ghedira N; Capri Y; Pouvreau N; Fillot N; Trimouille A; Vignal C; Fenneteau O; Alembik Y; Alessandri JL; Blanchet P; Boute O; Bouvagnet P; David A; Dieux Coeslier A; Doray B; Dulac O; Drouin-Garraud V; Gérard M; Héron D; Isidor B; Lacombe D; Lyonnet S; Perrin L; Rio M; Roume J; Sauvion S; Toutain A; Vincent-Delorme C; Willems M; Baumann C; Verloes A
    Eur J Hum Genet; 2016 Aug; 24(8):1124-31. PubMed ID: 26757980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
    Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
    Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
    J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Juvenile myelomonocytic leukemia in a 16-year-old with Noonan syndrome: case report.
    Ortiz MV; Skoda-Smith S; Rauen KA; Allan RW; Slayton WB
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):569-72. PubMed ID: 22510777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
    Niihori T; Aoki Y; Ohashi H; Kurosawa K; Kondoh T; Ishikiriyama S; Kawame H; Kamasaki H; Yamanaka T; Takada F; Nishio K; Sakurai M; Tamai H; Nagashima T; Suzuki Y; Kure S; Fujii K; Imaizumi M; Matsubara Y
    J Hum Genet; 2005; 50(4):192-202. PubMed ID: 15834506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Juvenile myelomonocytic leukemia and Noonan syndrome.
    Choong K; Freedman MH; Chitayat D; Kelly EN; Taylor G; Zipursky A
    J Pediatr Hematol Oncol; 1999; 21(6):523-7. PubMed ID: 10598665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.
    Bessis D; Miquel J; Bourrat E; Chiaverini C; Morice-Picard F; Abadie C; Manna F; Baumann C; Best M; Blanchet P; Bursztejn AC; Capri Y; Coubes C; Giuliano F; Guillaumont S; Hadj-Rabia S; Jacquemont ML; Jeandel C; Lacombe D; Mallet S; Mazereeuw-Hautier J; Molinari N; Pallure V; Pernet C; Philip N; Pinson L; Sarda P; Sigaudy S; Vial Y; Willems M; Geneviève D; Verloes A; Cavé H
    Br J Dermatol; 2019 Jun; 180(6):1438-1448. PubMed ID: 30417923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia].
    Yang WY; Chen XJ; Wang SC; Guo Y; Liu TF; Chang LX; Liu F; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):1-5. PubMed ID: 25616283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
    Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making.
    Hofmans M; Schröder R; Lammens T; Flotho C; Niemeyer C; Van Roy N; Decaluwe W; Philippé J; De Moerloose B
    Br J Haematol; 2019 Nov; 187(4):E83-E86. PubMed ID: 31617209
    [No Abstract]   [Full Text] [Related]  

  • 38. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
    Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
    Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.